1. Home
  2. OI vs ANL Comparison

OI vs ANL Comparison

Compare OI & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo O-I Glass Inc.

OI

O-I Glass Inc.

SELL

Current Price

$5.94

Market Cap

932.7M

ML Signal

SELL

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

SELL

Current Price

$14.18

Market Cap

998.8M

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
OI
ANL
Founded
1903
2004
Country
United States
Singapore
Employees
N/A
N/A
Industry
Containers/Packaging
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
932.7M
998.8M
IPO Year
1994
2022

Fundamental Metrics

Financial Performance
Metric
OI
ANL
Price
$5.94
$14.18
Analyst Decision
Buy
Strong Buy
Analyst Count
9
7
Target Price
$8.81
★ $29.50
AVG Volume (30 Days)
★ 3.7M
176.6K
Earning Date
10-27-2026
08-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $6,426,000,000.00
N/A
Revenue This Year
N/A
$243.83
Revenue Next Year
$2.29
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$5.30
$0.88
52 Week High
$16.91
$17.25

Technical Indicators

Market Signals
Indicator
OI
ANL
Relative Strength Index (RSI) 42.59 44.40
Support Level $5.30 $12.07
Resistance Level $9.72 $15.29
Average True Range (ATR) 0.23 1.27
MACD 0.08 -0.17
Stochastic Oscillator 66.13 13.25

Price Performance

Historical Comparison
OI
ANL

About OI O-I Glass Inc.

O-I Glass is the manufacturer of glass containers. The Company has two reportable segments and two operating segments based on its geographic locations: Americas and Europe. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: